ERT Launches Phase I QT Center of Excellence

ERT announced the establishment of a Phase I QT Center of Excellence, which is an advanced technology that enables pharmaceutical companies, biotechs, and CROs to gain information and data about the cardiac safety profile of their drug candidates at the earliest possible time in the drug development process in order to meet regulatory requirements.

Read the full release here.